Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject was randomized into protocol 20120262 (NCT01970475) and completed the week 26 visit~Exclusion Criteria:~* Subject experienced a serious adverse event (SAE) or an adverse event (AE) in the 20120262 study that could cause extension treatment to be detrimental~* Subject completed study 20120262 but cannot be dosed within 4 weeks of the week 26 visit of study 20120262~* Current infection requiring the use of oral or intravenous antibiotics~Other Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- ABP 501 (Type: EXPERIMENTAL): Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).